|
E-case #2-B
Ru-Chien Chi, M.D.
June 18-22,2001
Editor's note:
Ru just returned from a month of work and travel in Nepal, and wanted
to share this case. She completes her IM training this month and will
be entering a geriatrics fellowship.
A 20 yr old previously healthy Nepali male presents with fatigue, cough,
hemoptysis, epistaxis, and 6-kg weight loss in 6 mos. Past medical history
is notable for taking OTC medication for "enteric fever." He's had pesticide
exposure from farming. Denies history of TB, tobacco/alcohol use, and
is not married. Exam is notable for a poorly nourished male without jaundice,
lymphadenopathy, or hepatosplenomegaly. Tachycardia and petechiae are
noted. Laboratory studies revealed WBC 2.3, Hb 5.0, Plt 36 K.
-
What's the differential diagnosis for pancytopenia?
-
What tests would you order?
Differential: "PANCITTO"
PNH
Aplastic anemia
Nutritional (folate, B12 deficiency)
Collagen vascular diseases (SLE, eosinophilic
fasciitis)
Infection (TB, EBV, seronegative hepatitis,
HIV)
Toxin (Alcohol, benzene, chloramphenicol, gold,
penicillamine, allopurinol, NSAIDS, sulfonamides, antithyroid, antiepileptics
and antipsychotropics drugs)
Tumor (Myelodysplasia Syndrome, leukemia/lymphoma,
myelofibrosis, myelophthisis, thymoma and thymic CA)
Other (Sarcoid, pregnancy, radiation, GVHD)
| Test |
Utility |
| CBC with differential |
Malignant vs. benign |
| Retic count |
Production vs. destruction |
| Bone marrow biopsy |
Cellularity, granuloma, fibrosis, leukemia, etc. |
| Bone marrow aspirate: |
|
Morphology
Cytogenetics
Culture |
Malignant vs. benign
Myelodysplasia, leukemia
Infectious agent (TB, virus) |
| LFTs, renal function |
Hepatitis, chronic renal failure |
| Serologic testing |
Viral entities such as EBV |
| Autoantibodies |
Evidence of collagen vascular disease |
| Ham test/ CD 59 |
PNH |
This patient was diagnosed with aplastic anemia, the most common
cause of pancytopenia in young adults. His bone marrow was hypoplastic
with less than 25% cellularity. His exposures included chloramphenicol
and insecticides. Most cases are idiopathic. The prognosis in aplastic
anemia is directly related to the quantitative reduction in peripheral
blood cell counts, particularly ANC. Mortality at two years is 80-90%
with patients treated only with blood transfusions and antibiotics. Bone
marrow or peripheral blood stem cell transplant are curative, with survival
rates as high as 90%. Immunosupression (antithymocyte globulin, cyclosporin)
is used in patients who are not candidates for transplant.
References
Brodsky, RA. Biology and management of acquired severe aplastic anemia.
Current Opin Oncol Mar 1998; 10(2):95-9.
Guinan, EC. Clinical aspects of aplstic anemia. Hematol Oncol Clin
N. Am. Dec 1997; 11(6): 1025-44.
Young, NS. Acquired aplastic anemia. JAMA. July 1999; 282(3): 271-8.
|